Antidiabetic Medications and the Risk of Colorectal Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis

Background: Antidiabetic medications (ADM) may modify colorectal cancer risk in patients with diabetes mellitus. We performed a systematic review and meta-analysis, evaluating the effect of metformin, thiazolidinediones (TZD), sulfonylureas, and insulin on colorectal cancer risk in diabetic patients. Methods: We conducted a systematic search of multiple bibliographic databases, up to September 2012, for articles that evaluated exposure to metformin, TZD, sulfonylureas, and insulin, reported colorectal cancer risk in patients with diabetes mellitus, and reported OR or provided data for their estimation. Summary OR estimates with 95% confidence intervals (CI) were estimated using the random-effects model. Results: Fifteen studies reporting 13,871 cases of colorectal cancer in 840,787 patients with diabetes mellitus were included. Meta-analysis of observational studies showed an 11% reduction in colorectal cancer risk associated with metformin use (n = 9 studies; OR, 0.89; 95% CI, 0.81–0.99), whereas TZD use was not associated with colorectal cancer risk (n = 5 studies; OR, 0.96; 95% CI, 0.87–1.05). Conversely, a trend toward higher colorectal cancer risk was observed with sulfonylurea (n = 7 studies; OR, 1.11; 95% CI, 0.97–1.26) and insulin (n = 9 studies; OR, 1.33; 95% CI, 0.91–1.94) use, although these associations were not statistically significant. There was considerable heterogeneity across studies, partly explained by study location and adjustment for concomitant use of other ADMs. Post-hoc analysis of randomized controlled trials did not reveal any significant association between ADM and colorectal cancer risk. Conclusions: Meta-analysis of published studies supports a protective association between metformin use and colorectal cancer risk in patients with diabetes mellitus. Impact: Clinical trials on the chemopreventive effect of metformin against colorectal cancer are warranted. Cancer Epidemiol Biomarkers Prev; 22(12); 2258–68. ©2013 AACR.

[1]  M. Murad,et al.  Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis , 2013, The American Journal of Gastroenterology.

[2]  M. Murad,et al.  Anti-Diabetic Medications and Risk of Pancreatic Cancer in Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis , 2013, The American Journal of Gastroenterology.

[3]  Samy Suissa,et al.  Metformin and the Risk of Cancer , 2012, Diabetes Care.

[4]  F. Kanwal,et al.  "Systematic Reviews and Meta-analyses" in Clinical Gastroenterology and Hepatology. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  C. Tseng.  Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. , 2012, European journal of endocrinology.

[6]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[7]  J. GarcíaSánchez.  [Colonoscopic polypectomy and long-term prevention of colorectal cancer deaths]. , 2012 .

[8]  C. la Vecchia,et al.  Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. , 2012, The oncologist.

[9]  M. Lai,et al.  Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. , 2012, The Journal of clinical endocrinology and metabolism.

[10]  M. Lai,et al.  Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus , 2012, Hepatology.

[11]  A. Chak,et al.  Insulin resistance, central obesity, and risk of colorectal adenomas , 2012, Cancer.

[12]  Hirokazu Takahashi,et al.  Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial , 2012, BMC Cancer.

[13]  Tetsuro Tsujimoto,et al.  Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis , 2012, PloS one.

[14]  A. Zauber,et al.  Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. , 2012, The New England journal of medicine.

[15]  A. Pariente,et al.  Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database , 2012, Diabetologia.

[16]  S. Jick,et al.  Use of Metformin Is Not Associated with a Decreased Risk of Colorectal Cancer: A Case–Control Analysis , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[17]  J. Coebergh,et al.  Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea Derivatives , 2011, Diabetes Care.

[18]  Derek LeRoith,et al.  Diabetes, cancer, and metformin: connections of metabolism and cell proliferation , 2011, Annals of the New York Academy of Sciences.

[19]  D. Corley,et al.  Is Diabetes Mellitus an Independent Risk Factor for Colon Cancer and Rectal Cancer? , 2011, The American Journal of Gastroenterology.

[20]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[21]  H. Kan,et al.  Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes , 2011, Diabetes Care.

[22]  J. Skinner,et al.  Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer , 2011, Diabetes Care.

[23]  G. Steineck,et al.  Insulin glargine use and short-term incidence of malignancies — a three-year population-based observation , 2011, Acta oncologica.

[24]  M. Woodward,et al.  Intensive glucose control and risk of cancer in patients with type 2 diabetes , 2011, Diabetologia.

[25]  A. Ferrara,et al.  Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes , 2011, Diabetes Care.

[26]  L. Uman.  Systematic reviews and meta-analyses. , 2011, Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent.

[27]  Meei-Shyuan Lee,et al.  Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals , 2011, BMC Cancer.

[28]  M. McCullough,et al.  Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. , 2010, Gastroenterology.

[29]  T. Okumura.  Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs , 2010, Journal of Gastroenterology.

[30]  Hirokazu Takahashi,et al.  Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial , 2010, Cancer Prevention Research.

[31]  Edward Giovannucci,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[32]  Hirokazu Takahashi,et al.  Metformin suppresses azoxymethane‐induced colorectal aberrant crypt foci by activating AMP‐activated protein kinase , 2010, Molecular carcinogenesis.

[33]  P. Home,et al.  Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials , 2010, Diabetologia.

[34]  E. Gale,et al.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.

[35]  P. Donnan,et al.  New Users of Metformin Are at Low Risk of Incident Cancer , 2009, Diabetes Care.

[36]  Christopher F. Martin,et al.  The Association between Diabetes, Insulin Use, and Colorectal Cancer among Whites and African Americans , 2009, Cancer Epidemiology Biomarkers & Prevention.

[37]  Kunihiro Hosono,et al.  Metformin suppresses intestinal polyp growth in ApcMin/+ mice , 2008, Cancer science.

[38]  M. Pollak,et al.  Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. , 2008, Endocrine-related cancer.

[39]  I. Ben-Sahra,et al.  The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level , 2008, Oncogene.

[40]  S. Oliveria,et al.  Cancer incidence among patients treated with antidiabetic pharmacotherapy , 2008 .

[41]  N. Qizilbash,et al.  Cancer risks in thiazolidinedione users compared to other anti‐diabetic agents , 2007, Pharmacoepidemiology and drug safety.

[42]  E. Siegel,et al.  Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Cerhan,et al.  Insulin, glucose, insulin resistance, and incident colorectal cancer in male smokers. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[44]  S. Majumdar,et al.  Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.

[45]  S. Larsson,et al.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[46]  R. Hayes,et al.  Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. , 2005, Gastroenterology.

[47]  J. Lewis,et al.  Type 2 diabetes mellitus and the risk of colorectal cancer. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[48]  A. Folsom,et al.  Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[49]  J. Lewis,et al.  Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. , 2004, Gastroenterology.

[50]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[51]  Douglas G Altman,et al.  Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.

[52]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[53]  S J Pocock,et al.  Randomized trials or observational tribulations? , 2000, The New England journal of medicine.

[54]  G A Colditz,et al.  Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. , 1999, Journal of the National Cancer Institute.

[55]  Junji Kato,et al.  Aberrant crypt foci of the colon as precursors of adenoma and cancer , 1998, The New England journal of medicine.

[56]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[57]  P. Easterbrook,et al.  Publication bias in clinical research , 1991, The Lancet.

[58]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[59]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[60]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[61]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[62]  Harm,et al.  Lower Risk of Cancer in Patients on Metformin in ComparisonWith Those on Sulfonylurea Derivatives Results from a large population-based follow-up study , 2011 .

[63]  J. Johnson,et al.  Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials , 2010, Diabetologia.

[64]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[65]  the Scottish Diabetes Research Network Epidemiology Group.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group , 2009, Diabetologia.

[66]  Juan Carlos Espinosa,et al.  Comprehensive Meta-Analysis , 2004 .

[67]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.